HALAVEN sol inj 1 mg/2ml flac 2 ml
7680594890015
CH-59489
L01XX41
07.16.1.
Reimbursement limitations:
HALAVEN3
Halaven est indiqué en monothérapie dans
- le traitement du cancer du sein HER2 négatif …
1 / 3
google
Details
- Product number
- 5948901
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- eribulini mesilas 1 mg corresp. eribulinum 0.88 mg, ethanolum anhydricum 0.1 ml, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad solutionem pro 2 ml.
Articles (1)
Halaven, Injektionslösung
Injektionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
1.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
0.88 MG | Substance | WIIS |
|
(N/A)
|
0.1 ML | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 221.60
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2011
Authorization holder
Eisai Pharma AG
8050 Zürich
Authorization information
- Swissmedic authorization number
- 59489
- Drug name
- Halaven, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- L01XX41
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 13/05/2011
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- HALAVEN sol inj 1 mg/2ml flac 2 ml
- Description (DE)
- HALAVEN Inj Lös 1 mg/2ml Durchstf 2 ml
- Market launch
- 13/05/2011
- Narcotic (BTM)
- No